

**ENANTIOSELECTIVE SYNTHESIS OF THE TETRAHYDROBENZYL-  
ISOQUINOLINE ALKALOID (-)-NORARMEPAVINE USING POLYMER  
SUPPORTED REAGENTS**

**Ian R. Baxendale, Thomas D. Davidson, Steven V. Ley, and Remedios H. Perni\***

Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge,  
UK CB2 1EW. E-mail\*: [rh286@cam.ac.uk](mailto:rh286@cam.ac.uk)

**Abstract** – We describe, in full, the enantioselective synthesis of the tetrahydrobenzylisoquinoline alkaloid (-)-norarmepavine (**1**) in 77% e.e. This compound was prepared using solid-supported reagents and scavengers in multi-step sequences of reactions to give materials that required no conventional purification at the individual steps.


The utilization of solid-supported reagents in chemical synthesis has been shown to markedly improve productivity in many critical aspects of the generation of new chemical entities and complex target molecules.<sup>1</sup> The potential to configure the reactions in both a serial and convergent fashion offers many distinct advantages compared to solid-phase on-bead synthesis. In addition, the simple removal of spent reagents through filtration enables reactions to be driven to completion through the addition of excess reagents and for lower yielding reactions to be worked up using scavenger resins. We have previously reported on the use of these concepts in the sequential multi-step synthesis of various natural products using solid-supported reagents and scavengers to effect all the individual steps.<sup>2</sup> As a consequence, no chromatographic purification procedures were necessary and all steps proceeded with minimum optimization. In order to extend these methods to the asymmetric synthesis of natural compounds we have investigated in this work the preparation of the tetrahydrobenzylisoquinoline alkaloid (-)-norarmepavine (**1**).<sup>3</sup>

Norarmepavine was isolated in 1963 from the American lotus, *Nelumbo lutea* (Nymphaeaceae).<sup>4</sup> This alkaloid has been tested for biological activity in three pharmacological screening procedures.<sup>4,5</sup> In mice it produces mydriasis, bradypnea and a decrease in spontaneous motor activity after oral doses of 200 mg/Kg.

At a dose of 100 mg/Kg only slight mydriasis in one out of two animals was observed whereas intraperitoneally, a dose of 50 mg/Kg caused writhing in the animal, however this effect is probably related to the low pH necessary to solubilize the compound. At a dose of 50 mg/Kg orally compound (1) exerted only a weak analgesic action in rats and failed to produce anti-pyresis or diminish edema in the Randall and Selitto anti-inflammatory test. In ether-chloralose anaesthetized cats (-)-norarmepavine produced transient depressor effects after being dosed at 10 mg/Kg intravenously but failed to alter the responses to standard agents affecting the autonomic nervous system.


To the best of our knowledge, the work below constitutes the first enantioselective total syntheses of this natural product using a sequence of polymer-supported reagents and only the second total synthesis of this alkaloid.<sup>6</sup>

Retrosynthetic analysis of (-)-norarmepavine (1) suggests the amine (4) and the ethyl ester (5) as suitable starting materials (Scheme 1). The desired core structure (2) could be formed via a Bischler-Napieralski cyclisation of 3 and the required stereochemistry would be obtained *via* enantioselective reduction of the imine (2).




The synthesis begins with commercially available 2-(3,4-dimethoxyphenyl)ethylamine (4) and ethyl 4-benzyloxyphenylacetate (5). Microwave irradiation (MW) under solvent-free conditions of a mixture of these components led to the amide (3) in better than 90 % yield (see Scheme 2).<sup>7</sup> The amide formed was pure enough to take through the next reaction without further purification. The route to the isoquinoline nucleus involved the Bischler-Napieralski reaction of the amide (3). Initial experiments to catalyse this reaction using trifluoromethanesulfonic anhydride (Tf<sub>2</sub>O)<sup>8</sup> and polymer-supported 4-dimethylaminopyridine (●-DMAP) in CH<sub>2</sub>Cl<sub>2</sub> followed by treatment with polymer-supported *N*-(2-aminoethyl)aminomethyl polystyrene (●-NH<sub>2</sub>), in order to destroy the excess of Tf<sub>2</sub>O, led to the iminium triflate (7) (see Scheme 3). Treatment *in situ* of the salt with polymer-supported 2-*tert*-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine (●-BEMP) generated the

free base (**2**).<sup>9</sup> In order to guarantee the success of this reaction, it is very important that the order and timing of the addition of the reagents is strictly followed (see Table 1). The best yields were obtained with the slow addition of a solution of Tf<sub>2</sub>O in CH<sub>2</sub>Cl<sub>2</sub> over 6 h to a mixture of the amide and **1**-DMAP at 0°C (Entry 5 in Table 1). If the addition of reagents is done faster the proportion of unreacted starting material increases dramatically.



(i) MW, 100°C 30 sec, 200°C 30 min, remove solvent 200°C 30 min 90%. (ii)(a) **1**-DMAP, Tf<sub>2</sub>O, DCM, 0°C; (b) **1**-NH<sub>2</sub>; (c) **1**-BEMP 67% (5:1) (imine (**2**) : amide (**3**)). (iii) (a) starting material added to the reducing agent dropwise over 15 min, (**10b**) in DCM at -35°C and slowly warmed until -10°C for 1 h and then at 0°C for 4 h, evaporation of solvent (b) Amberlyst 15 (**1**-SO<sub>3</sub>H), CH<sub>3</sub>OH (catch) 45 min then filtrated and release with NH<sub>3</sub>/CH<sub>3</sub>OH overnight. 82% e.e.=78% (Mosher ester), [α]<sub>D</sub><sup>20</sup> -12.4° (c=0.805, CHCl<sub>3</sub>). (iv) H<sub>2</sub>, Pd(OH)<sub>2</sub>/C, CH<sub>3</sub>OH, rt, overnight, 90%. e.e.=77% (Pirkle reagent)<sup>13</sup>, [α]<sub>D</sub><sup>20</sup> -9.5° (c=0.825, CHCl<sub>3</sub>)<sup>4,6, and 14</sup>

Scheme 2



Scheme 3



Finally, hydrogenation of the benzyl protecting group using palladium hydroxide on carbon in methanol lead to (-)-norarmepavine (**1**) in 90% yield. The enantiomeric excess of synthetic **1** was determined as 77% using  $^1\text{H}$  NMR spectroscopy in the presence of (*S*)-(+)-2,2,2-trifluoro-1-(9-anthryl)ethanol, chiral shift reagent.<sup>13</sup> All of the spectroscopic data for the synthetic material were identical in all respects with those of the naturally occurring compound.<sup>4,6,14</sup> The specific rotation of synthetic **1**  $[\alpha]_{\text{D}}^{20}$   $-9.5^\circ$  ( $c=0.825$ ,  $\text{CHCl}_3$ ) was in reasonable agreement with the literature<sup>4,6</sup> value  $[\alpha]_{\text{D}}^{25}$   $-23.0^\circ$  ( $c=1.33$ ,  $\text{CHCl}_3$ ) and supported the assignment of the absolute stereochemistry as (*S*).

## EXPERIMENTAL

$^1\text{H}$ -NMR spectra were recorded on a Bruker DPX-400 spectrometer and are reported as follows: chemical shift,  $^1\text{H}$  (ppm), (number of protons, multiplicity, coupling constant, *J* in Hertz). Spectra were recorded in  $\text{CDCl}_3$  unless otherwise stated.  $^{13}\text{C}$ -NMR and DEPT  $^{13}\text{C}$ -NMR spectra were recorded on a Bruker DPX-400 spectrometer and are recorded as follows: chemical shift,  $\delta_{\text{C}}$  (ppm), (assignment). Spectra were recorded in  $\text{CDCl}_3$  unless otherwise stated. Melting points were determined on a Gallenkamp melting point apparatus and are uncorrected. Infrared spectra were reported neat (film) on a Perkin Elmer Spectrum One FTIR spectrophotometer. MS spectra were obtained on a Kratos MS890MS spectrometer at the Department of Chemistry, University of Cambridge. Microwave experiments were performed on a Smith Synthesizer manufactured by Personal Chemistry, Upsala Sweden. All reactions were carried out under an argon atmosphere with dry solvents unless otherwise stated. THF was distilled from sodium benzophenone ketyl; dichloromethane (DCM) from  $\text{CaH}_2$ . All other reagents and solvents were used as supplied.

*Preparation of 2-(4-benzyloxyphenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]acetamide (3).* A mixture of 2-(3,4-dimethoxyphenyl)ethylamine (**4**) (2.5 g, 14 mmol) and ethyl 2-(4-benzyloxyphenyl)acetate (**5**) (3.78 g, 14 mmol) was subjected to microwave irradiation at 100 °C for 30 sec then at 200 °C for 30 min. The ethanol formed was removed under vacuum and the remaining residues subjected to microwave irradiation at 200 °C for a further 30 min, yielding a yellow/orange solid. This was recrystallised in  $\text{CH}_3\text{OH}$  to give a white crystalline solid (5.06 g, 90%): mp 115-116 °C (lit.,<sup>15</sup> mp 116 °C and 114-115 °C); IR  $\nu_{\text{max}}$  3321, 1639, 1541, 1511, 1236, 1143, 1022  $\text{cm}^{-1}$ ; HR-MS found 428.1846, calcd 428.1838 for  $\text{C}_{25}\text{H}_{27}\text{NO}_4\text{Na}^+$ ;  $^1\text{H}$ -NMR ( $\text{CDCl}_3$ )  $\delta$  = 7.45-7.31 (5H, m), 7.08 (2H, d, *J* = 8.55 Hz), 6.91 (2H, d, *J* = 8.55 Hz), 6.72 (1H, d, *J* = 8.13 Hz), 6.62 (1H, d, *J* = 1.90 Hz), 6.56 (1H, dd, *J* = 8.13 and 1.90 Hz), 5.44 (1H, br s), 5.05 (2H, s), 3.44 (2H, dd, *J* = 12.70 and 6.70 Hz), 2.67 (2H, t, *J* = 6.93 Hz);  $^{13}\text{C}$ -NMR  $\delta$  = 35.06 ( $\text{CH}_2$ ), 40.72 ( $\text{CH}_2$ ), 42.95 ( $\text{CH}_2$ ), 55.84 ( $\text{CH}_3$ ), 55.94 ( $\text{CH}_3$ ), 70.05 ( $\text{CH}_2$ ), 111.40 (CH), 111.86 (CH), 115.32 (2xCH), 120.62 (CH), 127.04 (C) 127.41 (2xCH), 128.02 (CH), 128.60 (2xCH), 130.52 (2xCH), 131.14 (C), 136.86 (C), 147.69 (C), 149.07 (C), 158.06 (C), 171.27 (C).

*Preparation of 1-(4-benzyloxybenzyl)-6,7-dimethoxy-3,4-dihydroisoquinoline (2) via Bischler-Napieralski cyclization.* A solution of Tf<sub>2</sub>O (0.55 mL, 3.36 mmol) in DCM (3 mL) was added over a period of 6 h to a cooled (ice-water bath) solution of the amide (**3**) (272 mg, 0.67 mmol) and **1**-DMAP (672 mg, 2.01 mmol) (Fluka Cat. N<sup>o</sup> 39410) in DCM (15 mL). 10 min after the addition **1**-NH<sub>2</sub> (2.5 g, 6.72 mmol) (Nova Biochem Cat. N<sup>o</sup> 01-64-0178 A26718) was added and the mixture shaken at rt for 16 h. **1**-BEMP (Aldrich Cat. No 53,649-0) was added and the mixture shaken for an additional 5 h. The reaction mixture was filtered, the resins washed with DCM, and the filtrate evaporated under reduced pressure to give the title compound (**2**) as a pale brown solid mp 108.5-109.8 °C (aqueous EtOH) (lit.,<sup>15b, 16</sup> mp 101 °C) (67% pure by LCMS plus 13% of starting material (**3**) and 5% of the oxidation product (**8**)): IR  $\nu_{\max}$  1605, 1570, 1510, 1248, 1211, 1143, 1018 cm<sup>-1</sup>; HR-MS found 410.1732, calcd 410.1717 for C<sub>25</sub>H<sub>25</sub>NO<sub>3</sub>Na<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  = 7.41-7.29 (5H, m), 7.22 (2H, d, J = 8.50 Hz), 6.89 (2H, d, J = 8.50 Hz), 6.97 (1H, s), 6.65 (1H, s), 5.02 (2H, s), 3.99 (2H, s), 3.88 (3H, s), 3.73 (3H, s), 3.73 (2H, t, J = 7.52 Hz), 2.65 (2H, t, J = 7.70 Hz); <sup>13</sup>C-NMR  $\delta$  = 25.77 (CH<sub>2</sub>), 45.53 (CH<sub>2</sub>), 47.07 (CH<sub>2</sub>), 55.89 (CH<sub>3</sub>), 56.00 (CH<sub>3</sub>), 69.98 (CH<sub>2</sub>), 109.76 (CH), 110.27 (CH), 115.03 (2xCH), 121.54 (C), 127.41 (2xCH), 127.86 (CH), 128.50 (2xCH), 129.52 (2xCH), 130.35 (C), 131.84 (C), 137.05 (C), 147.25 (C), 150.73 (C), 157.43 (C), 165.66 (C).

*Preparation of 1-(4-benzyloxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (6).*

*Preparation of the reducing agent (10a):* A solution of (*S*)-*N*-benzyloxycarbonylproline (**9a**) (400 mg, 1.61 mmol) in THF (1.0 mL) was added dropwise for 1 h to a stirred suspension of NaBH<sub>4</sub> (20.3 mg, 0.54 mmol) in THF (1.0 mL) at 0 °C (ice-water bath). After vigorous hydrogen evolution ceased, the mixture was stirred at rt for 6 h and then concentrated under reduced pressure.

*Preparation of the reducing agent (10b):* A solution of isobutyl chloroformate (4.4 mL, 34.04 mmol) in acetone (52 mL) was added dropwise to a mixture of L-proline (4.0 g, 34.74 mmol) and sodium bicarbonate (10.5 g, 125.0 mmol) in water (52 mL). The solution was stirred at rt overnight. After removal of the acetone, the aqueous solution was washed with ethyl acetate and acidified to pH 2 with concentrated hydrochloric acid, the temperature was maintained below 20 °C. The organic phase was separated and washed with brine and dried over anhydrous magnesium sulphate. The solvent was removed to give (*S*)-*N*-isobutyloxycarbonylproline (**9b**) as colorless oil. The spectroscopy data were in agreement with those reported in the literature.<sup>11d</sup>

A solution of the (*S*)-*N*-isobutyloxycarbonylproline (**9b**) (501.6 mg, 2.33 mmol) in THF (1.68 mL) was added dropwise over 10 min to a stirred suspension of NaBH<sub>4</sub> (29.1 mg, 0.77 mmol) in THF (1.68 mL) at

0°C (ice-water bath). After vigorous hydrogen evolution ceased, the mixture was stirred at rt overnight and then concentrated under reduced pressure.

To a cooled (-35°C) solution of **10b** (526.7 mg, 0.78 mmol) in DCM (3 mL) was added a solution of **2** (86 mg, 0.22 mmol) in DCM (3 mL) dropwise over 15 min. The mixture was allowed to warm to -10 °C over 1 h and then kept at 0°C for 4 h. The solvent was removed under vacuum and the residue dissolved in CH<sub>3</sub>OH (11 mL). After cooling to 0°C ●-SO<sub>3</sub>H (1 g, 2.22 mmol) (Fluka Cat. N° 06423) was added and the mixture shaken at rt for 45 min. The beads were filtered off and washed with DCM and CH<sub>3</sub>OH. A solution of ammonia in methanol (2M, 3.0 mL) at 0 °C was added and the mixture left shaking at rt overnight. The reaction mixture was filtered, the resins washed with DCM, and the filtrate evaporated under reduced pressure to give the title compound (**6**) as a pale yellow amorphous solid (71.1 mg, 82%): e.e.= 78% (determined by conversion to the corresponding Mosher ester).  $[\alpha]_D^{20}$  -12.4° (c=0.805, CHCl<sub>3</sub>). IR  $\nu_{\max}$  1609, 1582, 1508, 1258, 1220, 1111, 1019 cm<sup>-1</sup>, HR-MS found 412.1889, calcd 412.1886 for C<sub>25</sub>H<sub>27</sub>NO<sub>3</sub>Na<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  = 7.44-7.30 (5H, m), 7.17 (2H, d, J = 8.48 Hz), 6.95 (2H, d, J = 8.48 Hz), 6.62 (1H, s), 6.59 (1H, s), 5.05 (2H, s), 4.13-4.09 (1H, m), 3.85 (3H, s), 3.80 (3H, s), 3.23-3.12 (2H, m), 2.94-2.85 (2H, m), 2.80-2.66 (2H, m); <sup>13</sup>C-NMR  $\delta$  = 29.31 (CH<sub>2</sub>), 40.55 (CH<sub>2</sub>), 41.68 (CH<sub>2</sub>), 55.73 (CH<sub>3</sub>), 55.86 (CH<sub>3</sub>), 56.78 (CH), 69.95 (CH<sub>2</sub>), 109.46 (CH), 111.78 (CH), 114.92 (2xCH), 127.17 (C), 127.33 (2xCH), 127.82 (CH), 128.46 (2xCH), 130.26 (2xCH), 130.34 (C), 131.18 (C), 137.02 (C), 146.92 (C), 147.39 (C), 157.42 (C).

*Preparation of (-)-norarmepavine (I).* To a solution of **6** (60 mg, 0.155 mmol) in CH<sub>3</sub>OH (2.6 mL) was added Pd(OH)<sub>2</sub>-C (20%; 12 mg). The reaction mixture was stirred at rt under hydrogen for 22 h. The reaction mixture was filtered through cotton and then through celite and washed with CH<sub>3</sub>OH and DCM to give a pale yellow amorphous solid (41.5 mg, 90%) which required no further purification. e.e.= 77% (determined by chiral shift <sup>1</sup>H NMR (600 MHz) spectroscopy using (S)-(+)-2,2,2-trifluoro-1-(9-anthryl)ethanol.  $[\alpha]_D^{20}$  -9.5° (c=0.825, CHCl<sub>3</sub>). IR  $\nu_{\max}$  1611, 1513, 1257, 1223, 1111 cm<sup>-1</sup>; HR-MS found 300.1599, calcd 300.1601 for C<sub>18</sub>H<sub>22</sub>NO<sub>3</sub>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  = 7.03 (2H, d, J = 8.35 Hz), 6.65 (2H, d, J = 8.35 Hz), 6.58 (1H, s), 6.57 (1H, s), 4.20-4.17 (1H, m), 3.84 (3H, s, MeO), 3.79 (3H, s, MeO), 3.27-3.19 (1H, m), 3.11 (1H, dd, J = 4.73 and 13.94 Hz), 2.79-2.76 (2H, m); <sup>13</sup>C (CDCl<sub>3</sub>)  $\delta$  = 28.33 (CH<sub>2</sub>), 39.84 (CH<sub>2</sub>), 41.17 (CH<sub>2</sub>), 55.20 (CH<sub>3</sub>), 55.94 (CH<sub>3</sub>), 56.46 (CH), 109.59 (CH), 111.68 (CH), 115.91 (2xCH), 126.32 (C), 128.53 (C), 128.68 (C), 130.35 (2xCH), 147.24 (C), 147.77 (C), 155.75 (C).

## ACKNOWLEDGEMENTS

We gratefully acknowledge financial support from the BP endowment and the Novartis Research Fellowship (to S. V. L.) and R.H. Perni thanks the European Community for the Marie Curie Fellowship (contract N<sup>o</sup> HPMF-CT-2001-01336).

## REFERENCES AND NOTES

1. (a) S. V. Ley, I. R. Baxendale, R. N. Bream, P. S. Jackson, A. G. Leach, D. A. Longbottom, M. Nesi, J. S. Scott, R. I. Storer, and S. J. Taylor, *J. Chem. Soc., Perkin Trans. 1*, 2000, 3815; (b) S. V. Ley, I. R. Baxendale, G. Brusotti, M. Caldarelli, A. Massi, and M. Nesi, *Il Farmaco*, 2002, **57**, 321; (c) S. V. Ley and I. R. Baxendale, *Chem. Rec.*, 2002, **2**, 377; (d) *Supported Reagents and Scavengers in Multi-step Organic Synthesis*, I. R. Baxendale, R. I. Storer, and S. V. Ley in "Polymeric Materials in Organic Synthesis and Catalysis", ed. by M. R. Buchmeiser, VCH Berlin, ISBN 3-527-30630-7, 2003, 53.
2. (a) S. V. Ley, O. Schucht, A. W. Thomas, and P. J. Murray, *J. Chem. Soc., Perkin Trans. 1*, 1999, 1251; (b) J. Habermann, S. V. Ley, and J. S. Scott, *J. Chem. Soc., Perkin Trans. 1*, 1999, 1253; (c) I. R. Baxendale and S. V. Ley, *Bioorg. Med. Chem. Lett.*, 2000, **10**, 1983; (d) I. R. Baxendale, A. L. Lee, and S. V. Ley, *Synlett*, 2001, 1485; (e) I. R. Baxendale, S. V. Ley, and C. Piutti, *Angew. Chem., Int. Ed.*, 2002, **41**, 2194; (f) I. R. Baxendale, S. V. Ley, M. Nesi, and C. Piutti, *Tetrahedron*, 2002, **58**, 6285; (g) I. R. Baxendale, G. Brusotti, M. Matsuoka, and S. V. Ley, *J. Chem. Soc., Perkin Trans. 1*, 2002, 143; (h) I. R. Baxendale, A. L. Lee, and S. V. Ley, *J. Chem. Soc., Perkin Trans. 1*, 2002, 1850.
3. For other asymmetric synthesis using solid-supported reagents within the group see: (a) I. R. Baxendale, S. V. Ley, and C. Piutti, *Angew. Chem., Int. Ed.*, 2002, **41**, 2194; (b) I. R. Baxendale, S. V. Ley, C. Piutti, and M. Nesi, *Tetrahedron*, 2002, **58**, 6285; (c) I. R. Baxendale, G. Brusotti, M. Matsuoka, and S. V. Ley, *J. Chem. Soc., Perkin Trans. 1*, 2002, **2**, 143. (d) R. I. Storer, T. Takemoto, P. S. Jackson, and S. V. Ley, *Angew. Chem., Int. Ed.*, 2003, **42**, 2521.
4. S. M. Kupchan, B. Dasgupta, E. Fujita, and M. L. King, *Tetrahedron*, 1963, **19**, 227.
5. (a) M. L. Martin, M. T. Diaz, M. J. Montero, P. Prieto, and L. San Roman, *Planta Med.*, 1993, **59**, 63; (b) A. Morello, I. Lipchenca, B. K. Cassels, H. Speisky, J. Aldunate, and Y. Repetto, *Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology*, 1994, **107**, Part 3, 367; (c) A. Morello, I. Lipchenca, B. K. Cassels, H. Speisky, J. Aldunate, and Y. Repetto, *Comp. Biochem. Phys. C*, 1994, **107**, 367; (d) B. K. Cassels, M. Asencio, P. Conget, H. Speisky, L. A. Videla, and E. A. Lissi, *Pharmacol. Res.*, 1995, **31**, 103; (e) V. R. Hegde, P. Dai, C. Ladislaw, M. G. Patel, M. S. Puar, and J. A. Pachter, *Bioorg. Med. Chem. Lett.*, 1997, **7**, 1207; (f) M. A. Morales, S. E. Bustamante, G. Brito, D. Paz, and B. K. Cassels, *Phyther. Res.*, 1998, **12**, 103.
6. For the first stereoselective synthesis see K. Hashigaki, K. Kan, N. Qais, Y. Takeuchi, and M.



Yamato, *Chem. Pharm. Bull.*, 1991, **39**, 1126.

7. The best results are obtained when the mixture is first heated at 200 °C for 30 min followed by removal under vacuum of the ethanol liberated and heating again at 200 °C for another 30 min. In doing so, one avoids the cleavage of the amide to the starting materials which takes place over prolonged heating at high temperature in the presence of ethanol.
8. M. G. Banwell, B. D. Bissett, S. Busato, C. J. Cowden, D. C. R. Hockless, J. W. Holman, R. W. Read, and A. W. Wu, *J. Chem. Soc., Chem. Commun.*, 1995, 2551.
9. The spectroscopic data were in agreement to those obtained for the same compound obtained through a Bischler-Napieralski cyclization but using POCl<sub>3</sub> in reflux toluene (for experimental conditions see ref. 8 and references therein).
10. The asymmetric reduction of the imine has been achieved with good results by Noyori and Baker in solution using ruthenium and rhodium catalysts: (a) N. Uematsu, A. Fujii, S. Hashiguchi, T. Ikariya, and R. Noyori, *J. Am. Chem. Soc.*, 1996, **118**, 4916; (b) J. Mao and D. C. Baker, *Org. Lett.*, 1999, **1**, 841.
11. (a) A. J. Bose, F. Greer, and C. C. Price, *J. Org. Chem.*, 1958, **23**, 1335; (b) K. Yamada, M. Takeda, and T. Iwakuma, *Tetrahedron Lett.*, 1981, **22**, 3869; (c) K. Yamada, M. Takeda, and T. Iwakuma, *J. Chem. Soc., Perkin Trans. 1*, 1983, 265; (d) S. Atarashi, H. Tsurumi, T. Fujiwara, and I. Hayakawa, *J. Heterocyclic Chem.*, 1991, **28**, 329; (e) A. R. Hajipur and M. Hantehzadeh, *J. Org. Chem.*, 1999, **64**, 8475.
12. J. A. Dale and H. S. Mosher, *J. Am. Chem. Soc.*, 1973, **95**, 512.
13. H. S. Rzepa, M. L. Webb, A. M. Z. Slawin, and D. J. Williams, *J. Chem. Soc., Chem. Comm.*, 1991, 765.
14. C. Galeffi, R. La Bua, I. Messana, R. Z. Alcazar, and G. B. M. Bettolo, *Gazz. Chim. Ital.*, 1978, **108**, 97.
15. (a) P. Weiss, *J. Am. Chem. Soc.*, 1948, **70**, 4263; (b) T. Kametani, S. Takano, R. Yanase, C. Kibayashi, H. Iida, S. Kano, and K. Sakurai, *Chem. Pharm. Bull.*, 1966, **14**, 73.
16. T. Yamaguchi, *Chem. Pharm. Bull.*, 1953, **1**, 10.